With RRP (number = 41) | Without RRP (number = 329) | P valuea | |
---|---|---|---|
Age, years | 49.8 ± 12 (52.7) | 49.3 ± 11.5 (7) | 0.6 |
Sex | 31 (75.6%) | 240 (73%) | 0.85 |
Disease duration, weeks | 18.6 ± 8.4 (18.6) | 14.7 ± 8.1 (13) | 0.007 |
SJC in 28 joints | 8.6 ± 6.1 (8) | 7.8 ± 5.3 (7) | 0.5 |
< 14 | 31 (75.6) | 285 (86.6) | |
14 to 20 | 6 (14.6) | 32 (9.7) | 0.08 |
≥ 20 | 4 (12.2) | 12 (3.6) | |
TJC in 28 joints | 8.3 ± 6.3 (7) | 8.7 ± 6.9 (7) | 0.97 |
ESR, mm/1 hr | 32.6 ± 21.3 (30) | 32.7 ± 25.4 (25) | 0.5 |
CRP, mg/L | 26.2 ± 27.9 (14) | 24.6 ± 38.7 (11) | 0.12 |
< 4 | 4 (9.7) | 89 (27.1) | |
4 to 35 | 25 (61) | 168 (51.1) | 0.04 |
≥ 35 | 12 (29.3.8) | 72 (21.9) | |
Elevated ESR or CRP level | 38 (90.3) | 289 (87.8) | 0.45 |
DAS28(ESR)-4v | 5.3 ± 1.2 (5.4) | 5.3 ± 1.2 (5.2) | 0.8 |
RF positivity | 29 (70.7) | 175 (53.2) | 0.04 |
ACPA positivity | 31 (75.6) | 154 (46.8) | 0.0008 |
RF or ACPA positivity | 32 (78) | 190 (57.8) | 0.01 |
HAQ score | 0.95 ± 0.6 (1) | 1.04 ± 0.7 (1) | 0.5 |
Typical RA erosion | 18 (44) | 48 (14.6) | < 0.0001 |
Prednisone ≥ 7.5 mg/d | 2 (4.9) | 35 (10.6) | 0.4 |
≥ 5 mg/d | 7 (17.7) | 91 (27.7) | 0.19 |
Delay before 1st DMARD initiation ≥ 6 months after RA onset | 22 (53.7) | 147 (44.7) | 0.32 |
Satisfaction of 2010 ACR/EULAR criteria | 38 (92.7) | 278 (84.5) | 0.24 |